Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Santarus, Inc.

http://www.santarus.com/

Latest From Santarus, Inc.

Glumetza Patent Settlement Without An Authorized Generic Plus Price Hike Spawns Litigation

Walgreen and other retailers allege no-authorized generic patent settlement for extended-release metformin allowed Santarus (Valeant) to block generic entry for four years while raising the price more than 750%.

Legal Issues Intellectual Property

Profitable Pharming Expands Ruconest Potential And Resurrects Pompe Pipeline

Dutch rare disease company Pharming talked to Scrip about turning a profit for the first time in the company’s history, finally restocking the pipeline in potentially blockbuster indications, and turning its attention back to Pompe disease after 20 years in the cold.

Rare Diseases Companies

Pharming Turns A Profit After Reclaiming Ruconest

Pharming Group, a company that has been on the drug development scene since the ‘80s, has recorded a quarterly net profit for the first time – two years earlier than previously forecast.

Sales & Earnings Business Strategies

Pharming Regains Rights To Ruconest, Seizing More Control Over Its Destiny

The European specialty pharma will pay $60m upfront to Valeant to reacquire the rights to commercialize the hereditary angioedema treatment in North America.

Netherlands Business Strategies
See All

Company Information

  • Other Names / Subsidiaries
    • Covella Pharmaceuticals, Inc.
UsernamePublicRestriction

Register